DalsnaFinance

Molecular Partners $MOLN

Health Care

Switzerland
Create a scorecard

Live price temporarily unavailable.

Price history
Loading chart…

Molecular Partners (MOLN) is a Health Care company. Latest news and coverage below.

IPO: June 16, 2021 · $21.25 offering · NASDAQ · View IPO details →

Molecular Partners revenue & net income history (FY2019–FY2025)

RevenueNet income
CHF 189.6MCHF 62.9M−CHF 63.8MFY2019 revenue: CHF 20.4MFY2019 net income: −CHF 36.3M'19FY2020 revenue: CHF 9.34MFY2020 net income: −CHF 62.8M'20FY2021 revenue: CHF 9.75MFY2021 net income: −CHF 63.8M'21FY2022 revenue: CHF 189.6MFY2022 net income: CHF 117.9M'22FY2023 revenue: CHF 7.04MFY2023 net income: −CHF 62.0M'23FY2024 revenue: CHF 4.97MFY2024 net income: −CHF 54.0M'24FY2025 revenue: CHF 0FY2025 net income: −CHF 61.7M'25
Molecular Partners annual financial statements
FY2019Dec 2019FY2020Dec 2020FY2021Dec 2021FY2022Dec 2022FY2023Dec 2023FY2024Dec 2024FY2025Dec 2025
Income statement
RevenueCHF 20.4MCHF 9.34MCHF 9.75MCHF 189.6MCHF 7.04MCHF 4.97MCHF 0
Growth (year over year)—−54.2%+4.4%+1843.8%−96.3%−29.4%−100.0%
Operating income−CHF 36.7M−CHF 58.3M−CHF 63.4MCHF 116.6M−CHF 61.1M−CHF 61.2M−CHF 58.1M
Operating margin−179.9%−624.2%−650.2%61.5%−868.3%−1231.7%—
Net income−CHF 36.3M−CHF 62.8M−CHF 63.8MCHF 117.9M−CHF 62.0M−CHF 54.0M−CHF 61.7M
Net margin−178.0%−671.7%−653.9%62.2%−880.7%−1087.4%—
EPS (diluted)−CHF 1.69−CHF 2.51−CHF 2.06CHF 3.54−CHF 1.89−CHF 1.59−CHF 1.65
Balance sheet
Cash and equivalentsCHF 75.7MCHF 133.7MCHF 71.8MCHF 87.9MCHF 67.3MCHF 63.9MCHF 82.7M
Total assets—CHF 187.5MCHF 172.7MCHF 262.3MCHF 198.4MCHF 158.5MCHF 102.1M
Total liabilities—CHF 80.3MCHF 65.4MCHF 27.1MCHF 21.9MCHF 16.9MCHF 21.8M
Shareholders' equityCHF 54.1MCHF 107.2MCHF 107.3MCHF 235.2MCHF 176.4MCHF 141.6MCHF 80.3M
Cash flow
Operating cash flow−CHF 1.19M−CHF 29.0M−CHF 91.0MCHF 118.6M−CHF 59.0M−CHF 59.2M−CHF 51.3M
Capital expenditureCHF 1.03MCHF 1.45MCHF 933.0KCHF 1.18MCHF 575.0KCHF 705.0KCHF 714.0K
Free cash flow−CHF 2.22M−CHF 30.4M−CHF 91.9MCHF 117.4M−CHF 59.6M−CHF 60.0M−CHF 52.0M
Share buybacks—CHF 0CHF 0CHF 631.0KCHF 0CHF 0—

From Molecular Partners's 20-F and 6-K filings with the SEC; its fiscal year ends in December. Each period shows the latest figure the company has reported for it, including restatements. Amounts are in Swiss Franc (CHF), as reported, not converted to dollars. Per-share figures are per ordinary share, which is not always the share traded in the US: an ADS can stand for several, or for part of one. † Quarter derived from the company's year-to-date or full-year totals. Filings on SEC EDGAR →

About Molecular Partners

Molecular Partners AG is a clinical-stage biopharmaceutical company based in Zürich, Switzerland. The company is developing a new class of potent, specific and versatile small-protein therapies called DARPins, with potential clinical applications in a range of disease areas including oncology, immuno-oncology, ophthalmology, and infectious diseases. Molecular Partners currently has two DARPin molecules in clinical development, and a broad pipeline of molecules in preclinical development.

Source: Wikipedia — Molecular Partners

Headquarters
Schlieren-Zurich, Switzerland From SEC filings, Oct 2026

Recent News

No recent news mentioning Molecular Partners in our feed yet.

More Health Care stocks

Browse all companies →